Loading...
XNASNVAX
Market cap1.49bUSD
Jan 10, Last price  
9.32USD
1D
-3.02%
1Q
-25.66%
Jan 2017
-63.04%
Name

Novavax Inc

Chart & Performance

D1W1MN
XNAS:NVAX chart
P/E
—
P/S
1.52
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
40.37%
Rev. gr., 5y
95.68%
Revenues
984m
-38.48%
8,260,0007,388,0004,683,0001,513,0001,064,000325,000343,00014,688,00022,076,00020,915,00030,659,00036,250,00015,353,00031,176,00034,288,00018,662,000475,598,0001,146,290,0001,598,951,000983,705,000
Net income
-545m
L-17.16%
-25,920,000-11,174,000-23,068,000-34,765,000-36,049,000-38,374,000-35,708,000-19,364,000-28,507,000-51,983,000-82,947,000-156,937,000-279,966,000-183,769,000-184,748,000-130,102,000-427,505,000-1,743,751,000-657,939,000-545,062,000
CFO
-714m
L+71.65%
-30,099,000-5,809,000-14,810,000-26,742,000-24,310,000-32,830,000-32,852,000-23,629,000-18,229,000-45,359,000-67,014,000-126,090,000-255,467,000-138,696,000-184,825,000-136,623,000-42,541,000322,946,000-415,937,000-713,967,000
Earnings
Feb 26, 2025

Profile

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
URL
https://www.novavax.com/
IPO date
May 16, 1973
Employees
1,992
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
983,705
-38.48%
1,598,951
39.49%
Cost of revenue
1,081,270
2,626,608
Unusual Expense (Income)
NOPBT
(97,565)
(1,027,657)
NOPBT Margin
Operating Taxes
2,031
4,292
Tax Rate
NOPAT
(99,596)
(1,031,949)
Net income
(545,062)
-17.16%
(657,939)
-62.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
360,243
249,230
BB yield
-74.48%
-31.01%
Debt
Debt current
5,142
352,077
Long-term debt
285,004
256,138
Deferred revenue
622,210
179,414
Other long-term liabilities
90,982
55,695
Net debt
(283,240)
(730,327)
Cash flow
Cash from operating activities
(713,967)
(415,937)
CAPEX
(58,806)
(92,985)
Cash from investing activities
(58,806)
(92,985)
Cash from financing activities
4,466
324,988
FCF
296,011
(1,308,408)
Balance
Cash
568,505
1,336,883
Long term investments
4,881
1,659
Excess cash
524,201
1,258,594
Stockholders' equity
(4,816,824)
(4,281,398)
Invested Capital
4,926,466
4,432,210
ROIC
ROCE
EV
Common stock shares outstanding
100,768
78,183
Price
4.80
-53.31%
10.28
-92.81%
Market cap
483,686
-39.82%
803,721
-92.45%
EV
200,446
73,394
EBITDA
(56,340)
(998,603)
EV/EBITDA
Interest
14,416
19,880
Interest/NOPBT